Treatment of severe, recalcitrant, major aphthous stomatitis with adalimumab.
We describe an 18-year-old man with a 7-year history of severe major aphthous stomatitis refractory to multiple standard therapies who responded completely to therapy with adalimumab, a fully humanized monoclonal antibody against tumor necrosis factor alpha (TNF-alpha).
Vujevich
Justin
J
Department of Dermatology, University of Pittsburgh Physicians, Pennsylvania, USA.
Zirwas
Matthew
M
D000068879:Adalimumab; D000293:Adolescent; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D006801:Humans; D008297:Male; D012008:Recurrence; D013281:Stomatitis, Aphthous / Q000188:drug therapy*; D014409:Tumor Necrosis Factor-alpha / Q000276:immunology
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D014409:Tumor Necrosis Factor-alpha; D000068879:Adalimumab